Circulating tumor cells (CTCs) are shed from the primary tumor into the bloodstream and represent dynamic molecular biomarkers for monitoring the progression of cancer. While profiling tumor tissues with over expression of cell surface markers, such as PD-L1 or HER2, is standard in guiding therapy, tissue samples are often inaccessible and inadequate, especially post-surgery or in cases of recurrence. Emerging clinical evidence indicates that CTC counts and biomarker surface expression can predict prognosis and therapeutic resistance more accurately than imaging or tissue-based approaches. Recent advancements in the CTC detection methods, based on physical properties or surface markers (e.g., EpCAM), coupled with next-generation sequencing (NGS) have enabled the isolation of these rare cells and their molecular characterization. Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible.
Building similarity graph...
Analyzing shared references across papers
Loading...
Saloni Andhari
Jaspreet Farmaha
Ashutosh Vashisht
Cancers
Augusta University
FuelCell Energy (United States)
Tatyasaheb Kore Dental College and Research Centre
Building similarity graph...
Analyzing shared references across papers
Loading...
Andhari et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69a75b7fc6e9836116a22ec5 — DOI: https://doi.org/10.3390/cancers18030391